51
|
Zhao XS, Han B, Zhao JX, Tao N, Dong CY. MiR-155-5p affects Wilms' tumor cell proliferation and apoptosis via targeting CREB1. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2021; 25:6826. [PMID: 34859841 DOI: 10.26355/eurrev_202111_27223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The article "MiR-155-5p affects Wilms' tumor cell proliferation and apoptosis via targeting CREB1", by X.-S. Zhao, B. Han, J.-X. Zhao, N. Tao, C.-Y. Dong, published in Eur Rev Med Pharmacol Sci 2019; 23 (3): 1030-1037-DOI: 10.26355/eurrev_201902_16990-PMID: 30779069, has been retracted by the authors due to a slight deviation in the data. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/16990.
Collapse
|
52
|
Han B, Tian P, Zhao Y, Yu X, Guo Q, Yu Z, Zhang X, Li Y, Chen L, Shi X, Zhang Y, Wang J. 148P A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced non-squamous NSCLC patients failed to EGFR TKI therapies: First analysis. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
53
|
Han B, Li K, Wang Q, Cheng Y, Yang L, Li Y. LBA4 The efficacy and safety of TQ-B2450 alone/with anlotinib in previously treated advanced non-small cell lung cancer (NSCLC): A multicenter, randomized, double-blind, placebo-controlled clinical trial. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.219] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
54
|
Rhee C, Kang Y, Han B, Kim YW, Her M, Jeong W, Kim S. Virucidal efficacy of seven active substances in commercial disinfectants used against H9N2 low pathogenic avian influenza virus. J APPL POULTRY RES 2021. [DOI: 10.1016/j.japr.2021.100198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
55
|
Han B, Kovalchuk N, Capaldi D, Simiele E, White J, Purwar A, Yeung T, Maganti S, Mitra A, Voronenko Y, Oderinde O, Shirvani S, Kuduvalli G, Vitzthum L, Chang D, Xing L, Surucu M. First Beam Commissioning Report of a Novel Medical Linear Accelerator Designed for Biologically Guided Radiotherapy. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
56
|
Han B, Kovalchuk N, Capaldi D, Purwar A, Sun Z, Ye J, Moghadam A, Laurence T, Vitzthum L, Chang D, Xing L, Surucu M. The kVCT System Commissioning of a Novel Medical Linear Accelerator Designed for Biology-Guided Radiotherapy. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
57
|
Pham D, Breitkreutz D, Simiele E, Capaldi D, Ngo N, Vitzthum L, Gensheimer M, Chin A, Han B, Surucu M, Xing L, Chang D, Kovalchuk N. SBRT Treatment Planning Study for the First Clinical Biology-Guided Radiotherapy System. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
58
|
Surucu M, Maniyedath A, Narayanan M, Han B, Kovalchuk N, Gensheimer M, Vitzthum L, Iagaru A, Ferri V, Xing L, Shirvani S, Chang D. Comparison of a First-in-Class LINAC-Integrated PET System and a Diagnostic PET/CT Scanner. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1411] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
59
|
Xiong A, Li C, Xu J, Yang X, Nie W, Zhong H, Chu T, Zhang W, Zhong R, Pan F, Shen Y, Lou Y, Zhang B, Han B, Zhang X. FP12.06 Solid Subtype Predicts Early Bone Metastases in Sensitive EGFR-Mutated Lung Adenocarcinoma Patients After Surgery. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
60
|
Wang J, Wang Z, Wu L, Li B, Cheng Y, Li X, Wang X, Han L, Wu X, Fan Y, Yu Y, Lv D, Shi J, Huang J, Zhou S, Han B, Sun G, Guo Q, Ji Y, Zhu X, Hu S, Zhang W, Wang Q, Jia Y, Wang Z, Song Y, Wu J, Shi M, Li X, Han Z, Liu Y, Yu Z, Liu A, Wang X, Zhou C, Zhong D, Miao L, Zhang Z, Zhao H, Yang J, Wang D, Wang Y, Li Q, Zhang X, Ji M, Yang Z, Cui J, Gao B, Wang B, Liu H, Nie L, He M, Jin S, Gu W, Shu Y, Zhou T, Feng J, Yang X, Huang C, Zhu B, Yao Y, Wang Y, Kang X, Yao S, Keegan P. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.08.181] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
61
|
Iannaccone S, Phan H, Straub V, Muntoni F, Koenig E, Malhotra J, Han B, Darton E, Mercuri E. DMD - TREATMENT. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
62
|
Iff J, Bungey G, Paine A, Han B, Gordish-Dressman H, Henricson E, McDonald C. DMD - TREATMENT. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
63
|
Qi M, Jiao M, Li X, Hu J, Wang L, Zou Y, Zhao M, Zhang R, Liu H, Mi J, Zhang L, Liu L, Gong Y, Han B. Correction: CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2. Oncogene 2021; 40:6140-6141. [PMID: 34584220 DOI: 10.1038/s41388-021-01995-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
64
|
Han B, Yan B, Gu A, Chu T, Zhang W, Wang H, Zhong H, SHI C, Zhang X. 1238P AUTOMAN: A phase Ib/IIa study of osimertinib combined with anlotinib in EGFRm, treatment-naive advanced NSCLC patients. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
65
|
Han B, Yang Z, Wang Y, Chen Y, Qian F, Zhang Y, Hu M, Zhang W. 1163P Combined large cell neuroendocrine carcinoma: Clinical characteristics, prognosis and postoperative management. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
66
|
Zhou Q, Kim H, Soo R, Chang GC, Chiu CH, Hayashi H, Kim SW, Teraoka S, Goto Y, Zhou J, Lee V, Han B, Ho J, Kim DW, Lin CC, Lu S, Polli A, Calella A, Mok T, Wu YL. 1197P First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
67
|
Han B, Wang S, Li G, Wang X, Chen Z, Zhao G, Chen Y, Li M, Li Y, Zhang M, Ai S. [Objective sleep characteristics and risk factors for sleep apnea in heart failure patients with different left ventricular ejection fraction]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2021; 41:1415-1419. [PMID: 34658358 DOI: 10.12122/j.issn.1673-4254.2021.09.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To investigate the objective sleep characteristics and the independent risk factors for sleep apnea in heart failure (HF) patients with different left ventricular ejection fractions (LVEF). METHODS A total of 107 patients with chronic HF hospitalized in the Department of Cardiology of our hospital from April, 2019 to October, 2020 were included in this study. According to the LVEF measured by echocardiography, the patients were divided into reduced ejection fraction (HFrEF) group (n=35), mid-range ejection fraction (HFmrEF) group (n=21), and preserved ejection fraction (HFpEF) group (n=51). The baseline demographic and clinical characteristics of the patients were recorded. To assess the objective sleep characteristics, whole night polysomnography was scheduled for all the patients. Spearman correlation and multinomial logistic regression analyses were used to explore the factors affecting objective sleep characteristics. RESULTS The patients in HFpEF group had significantly lower proportion of non-rapid eye movement sleep stage 1, apnea hypopnea index (AHI), and central sleep apnea (CSA) than those in HFrEF group (all P < 0.05). The baseline demographic data or sleep structures in HFmrEF group did not differ significantly from those in the other two groups. Spearman correlation analysis revealed significant correlations of the male sex, diuretics use, NT-proBNP, LVEF, and total cholesterol levels with the severity of AHI (all P < 0.05). After adjusting for potential confounders, multiple logistics regression analysis showed that age, drinking, and LVEF levels were independently associated with the severity of AHI (all P < 0.05). CONCLUSION Abnormal objective sleep architectures occur in all HF patients, manifested mainly by sleep apnea. The incidences of sleep apnea and CSA are lower in patients with HFpEF than in those with HFrEF. Age, drinking, and LVEF levels are independent risk factors for the occurrence and severity of sleep apnea.
Collapse
|
68
|
Lackner L, Dusel M, Egorov OA, Han B, Knopf H, Eilenberger F, Schröder S, Watanabe K, Taniguchi T, Tongay S, Anton-Solanas C, Höfling S, Schneider C. Tunable exciton-polaritons emerging from WS 2 monolayer excitons in a photonic lattice at room temperature. Nat Commun 2021; 12:4933. [PMID: 34400620 PMCID: PMC8368091 DOI: 10.1038/s41467-021-24925-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2021] [Accepted: 07/01/2021] [Indexed: 11/30/2022] Open
Abstract
Engineering non-linear hybrid light-matter states in tailored lattices is a central research strategy for the simulation of complex Hamiltonians. Excitons in atomically thin crystals are an ideal active medium for such purposes, since they couple strongly with light and bear the potential to harness giant non-linearities and interactions while presenting a simple sample-processing and room temperature operability. We demonstrate lattice polaritons, based on an open, high-quality optical cavity, with an imprinted photonic lattice strongly coupled to excitons in a WS2 monolayer. We experimentally observe the emergence of the canonical band-structure of particles in a one-dimensional lattice at room temperature, and demonstrate frequency reconfigurability over a spectral window exceeding 85 meV, as well as the systematic variation of the nearest-neighbour coupling, reflected by a tunability in the bandwidth of the p-band polaritons by 7 meV. The technology presented in this work is a critical demonstration towards reconfigurable photonic emulators operated with non-linear photonic fluids, offering a simple experimental implementation and working at ambient conditions.
Collapse
|
69
|
Han B, Li Q, Wang C, Chandrasekaran P, Zhou Y, Qin L, Liu XS, Enomoto-Iwamoto M, Kong D, Iozzo RV, Birk DE, Han L. Differentiated activities of decorin and biglycan in the progression of post-traumatic osteoarthritis. Osteoarthritis Cartilage 2021; 29:1181-1192. [PMID: 33915295 PMCID: PMC8319061 DOI: 10.1016/j.joca.2021.03.019] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Revised: 03/01/2021] [Accepted: 03/19/2021] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To delineate the activities of decorin and biglycan in the progression of post-traumatic osteoarthritis (PTOA). DESIGN Three-month-old inducible biglycan (BgniKO) and decorin/biglycan compound (Dcn/BgniKO) knockout mice were subjected to the destabilization of the medial meniscus (DMM) surgery to induce PTOA. The OA phenotype was evaluated by assessing joint structure and sulfated glycosaminoglycan (sGAG) staining via histology, surface collagen fibril nanostructure and calcium content via scanning electron microscopy, tissue modulus via atomic force microscopy-nanoindentation, as well as subchondral bone structure and meniscus ossification via micro-computed tomography. Outcomes were compared with previous findings in the inducible decorin (DcniKO) knockout mice. RESULTS In the DMM model, BgniKO mice developed similar degree of OA as the control (0.44 [-0.18 1.05] difference in modified Mankin score), different from the more severe OA phenotype observed in DcniKO mice (1.38 [0.91 1.85] difference). Dcn/BgniKO mice exhibited similar histological OA phenotype as DcniKO mice (1.51 [0.97 2.04] difference vs control), including aggravated loss of sGAGs, salient surface fibrillation and formation of osteophyte. Meanwhile, Dcn/BgniKO mice showed further cartilage thinning than DcniKO mice, resulting in the exposure of underlying calcified tissues and aberrantly high surface modulus. BgniKO and Dcn/BgniKO mice developed altered subchondral trabecular bone structure in both Sham and DMM groups, while DcniKO and control mice did not. CONCLUSION In PTOA, decorin plays a more crucial role than biglycan in regulating cartilage degeneration, while biglycan is more important in regulating subchondral bone structure. The two have distinct activities and modest synergy in the pathogenesis of PTOA.
Collapse
|
70
|
Yao Y, Zhang C, Xiong Y, Han B, Gao X, Wang S. [miR-let-7c-5p inhibits invasion and migration of bladder cancer cells by targeting HMGA2]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2021; 41:1022-1029. [PMID: 34308851 DOI: 10.12122/j.issn.1673-4254.2021.07.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To investigate whether miR-let-7c-5p inhibits invasion and migration of bladder cancer cells by regulating HMGA2. METHODS We used bioinformatics methods to determine the key genes of miR-let-7c-5p. RT-qPCR and Western blotting were used to detect the expressions of miR-let-7c-5p mRNA and HMGA2 protein in bladder cancer and adjacent tissues. With human normal bladder SV-HUC-1 cells as the control, we detected the expression levels of miR-let-7c-5p mRNA and HMGA2 protein in bladder cancer cell lines T24, UM-UC-3 and 5637 with RT-qPCR and Western blotting. We observed the effects of miR-let-7c-5p upregulation (by transfection with a miR-let-7c-5p mimic), miR-let-7c-5p downregulation (using a miR-let-7c-5p inhibitor), and knockdown of both HMGA2 and miR-let-7c-5p on invasion, migration and expressions of epithelial-mesenchymal transition (EMT)-related proteins (E-cadherin, N-cadherin, vimentin, and Snail) in UM-UC-3 cells. Dual luciferase assay, RT-qPCR and Western blotting were used to verify the targeting relationship between miR-let-7c-5p and HMGA2. RESULTS HMGA2 was identified as one of the target genes of miR-let-7c-5p. Compared with the adjacent tissues, bladder cancer tissues showed a significantly decreased expression of miR-let-7c-5p and an increased expression of HMGA2 protein (P < 0.05). In UM-UC-3 cells, the expression of miR-let-7c-5p was significantly reduced and that of HMGA2 was significantly increased as compared with those in SV-HUC-1 cells (P=0.001). Up-regulating miR-let-7c-5p expression significantly lowered the invasion and migration abilities of UM-UC-3 cells, and down-regulating miR-let-7c-5p expression obviously promoted the invasion and migration of UM-UC-3 cells (P < 0.05). Knockdown of both miR-let-7c-5p and HMGA2 expression significantly lowered the invasion and migration (P < 0.05) and inhibited the expressions of EMT-related proteins of UM-UC-3 cells (P < 0.05). CONCLUSION miR-let-7c-5p inhibits EMT of bladder cancer UM-UC-3 cells by targeting HMGA2, thereby inhibiting the cell invasion and migration.
Collapse
|
71
|
Cho S, Lee D, Han B, Lee J, Hong J, Chung J, Lee D, Na J. 463 Automated atopic dermatitis severity assessment based on convolutional neural networks. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
72
|
Hu M, Lu J, Han B. 20P Synergistic inhibition of growth of KRAS-driven NSCLC by MEK inhibitor in combination with a novel multi-target tyrosine kinase inhibitor anlotinib via IGFBP-mediated signaling. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01862-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
73
|
Ling X, Xu J, Zhong R, Zhong H, Han B. 101MO Efficacy and safety of DCVAC/LuCa with chemotherapy for patients with stage IV NSCLC: A prospective, open-label, single-arm, phase II study. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01943-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
74
|
Yu L, Xu J, Qiao R, Zhong H, Han B, Zhong R. 59P Patterns of recurrence and survival after complete resection of pathological stage N2 small cell lung cancer. J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01901-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
75
|
Cui L, Wang LL, Li XJ, Wang LG, Li MZ, Han B. [Hypertrophic cardiomyopathy complicated with apical left ventricular aneurysm and ventricular tachycardia: a case report]. ZHONGHUA XIN XUE GUAN BING ZA ZHI 2021; 49:276-277. [PMID: 33706463 DOI: 10.3760/cma.j.cn112148-20200413-00307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
|